
Neonatal fragment crystallizable receptor - Wikipedia
FcRn is highly expressed during the neonatal period, particularly in epithelial and endothelial cells, to support passive immunity through maternal IgG transfer and protection from protein degradation.
Neonatal Fc Receptor — Biology and Therapeutics
Apr 23, 2025 · FcRn protects IgG and albumin from catabolism, transports IgG across the placenta, and regulates IgG function. Blocking or augmenting FcRn can decrease autoimmune antibodies and …
The neonatal Fc receptor, FcRn, as a target for drug delivery and ...
FcRn is the central regulator of IgG and albumin homeostasis throughout life and is increasingly being recognized as an important player in autoimmune disease, mucosal immunity, and tumor immune …
The therapeutic age of the neonatal Fc receptor - Nature
Feb 1, 2023 · Neonatal Fc receptor (FcRn) supports host defence through its role in antibody recycling and transcytosis, as well as by regulating immune effector cells together with classical Fc receptors...
Blocking FcRn in humans reduces circulating IgG levels and
Recently, several clinical studies have reported the lowering of circulating monomeric IgG levels through FcRn blockade for the potential treatment of autoimmune diseases. Many autoimmune diseases, …
The Neonatal Fc Receptor (FcRn): A Misnomer? - Frontiers
Jul 10, 2019 · Among the atypical FcγRs, the neonatal Fc receptor (FcRn) has increasingly gained notoriety given its intimate influence on IgG biology and its ability to also bind to albumin.
Neonatal Fc receptor in human immunity: Function and role in ...
Apr 2, 2020 · FcRn is an MHC class I–related receptor, consisting of a heterodimer of a heavy (α)-chain and β2-m. It binds IgG (Fc region) and albumin at separate binding sites on opposite sides of the α1 …
Optimizing human FcRn mouse models to improve pharmacokinetic ...
Mar 25, 2026 · The use of animal models that can reliably predict drug performance in human patients is critical to antibody therapeutic development. Along with assessing toxicity and efficacy, determining …
Efficacy and safety of complement inhibitors and FcRn blockers in ...
3 days ago · In AChR-Ab⁺ gMG, complement inhibitors and FcRn blockers yield clinically meaningful improvements with favourable safety profiles. Complement inhibition additionally confers sustained …
Roivant and Immunovant Solidify Market Leadership as Brepocitinib …
2 days ago · As of April 2, 2026, Roivant has reached a multi-year valuation peak, fueled by the success of its brepocitinib program and the strategic validation of its neonatal Fc receptor (FcRn) franchise.